Tenaya Therapeutics, Inc.
TNYA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $2 | $2 | $0 | $0 |
| Gross Profit | -$2 | -$2 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $15 | $17 | $21 | $19 |
| G&A Expenses | $0 | $7 | $6 | $6 |
| SG&A Expenses | $4 | $7 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | $0 | $0 |
| Operating Expenses | $19 | $22 | $28 | $25 |
| Operating Income | -$21 | -$24 | -$28 | -$25 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $1 | $1 |
| Pre-Tax Income | -$20 | -$23 | -$27 | -$24 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$20 | -$23 | -$27 | -$24 |
| % Margin | – | – | – | – |
| EPS | -0.12 | -0.14 | -0.24 | -0.28 |
| % Growth | 14.3% | 41.7% | 14.3% | – |
| EPS Diluted | -0.12 | -0.14 | -0.24 | -0.28 |
| Weighted Avg Shares Out | 163 | 163 | 110 | 86 |
| Weighted Avg Shares Out Dil | 163 | 163 | 110 | 86 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $3 | $2 |
| EBITDA | -$18 | -$21 | -$25 | -$23 |
| % Margin | – | – | – | – |